Department of Pharmacology, Faculty of Medicine, University of Murcia, Murcia, Spain.
Unit of Acute Psychiatry, Reina Sofía University Hospital, Av Intendente Jorge Palacios 1, 30003, Murcia, Spain.
Naunyn Schmiedebergs Arch Pharmacol. 2018 Apr;391(4):423-434. doi: 10.1007/s00210-018-1470-z. Epub 2018 Jan 30.
Methamphetamine (METH) addiction is a major public health problem in some countries. There is evidence to suggest that METH use is associated with increased risk of developing cardiovascular problems. Here, we investigated the effects of chronic METH administration and withdrawal on the activation of the brain stress system and cardiac sympathetic pathways. Mice were treated with METH (2 mg/kg, i.p.) for 10 days and left to spontaneous withdraw for 7 days. The number of corticotrophin-releasing factor (CRF), c-Fos, and CRF/c-Fos neurons was measured by immunohistochemistry in the paraventricular nucleus of the hypothalamus (PVN) and the oval region of the bed nucleus of stria terminalis (ovBNST), two regions associated with cardiac sympathetic control. In parallel, levels of catechol-o-methyl-transferase (COMT), tyrosine hydroxylase (TH), and heat shock protein 27 (Hsp27) were measured in the heart. In the brain, chronic-METH treatment enhanced the number of c-Fos neurons and the CRF neurons with c-Fos signal (CRF/c-Fos) in PVN and ovBNST. METH withdrawal increased the number of CRF neurons. In the heart, METH administration induced an increase in soluble (S)-COMT and membrane-bound (MB)-COMT without changes in phospho (p)-TH, Hsp27, or pHsp27. Similarly, METH withdrawal increased the expression of S- and MB-COMT. In contrast to chronic treatment, METH withdrawal enhanced levels of (p)TH and (p)Hsp27 in the heart. Overall, our results demonstrate that chronic METH administration and withdrawal activate the brain CRF systems associated with the heart sympathetic control and point towards a METH withdrawal induced activation of sympathetic pathways in the heart. Our findings provide further insight in the mechanism underlining the cardiovascular risk associated with METH use and proposes targets for its treatment.
甲基苯丙胺(METH)成瘾是一些国家的主要公共卫生问题。有证据表明,METH 的使用与心血管问题风险增加有关。在这里,我们研究了慢性 METH 给药和戒断对大脑应激系统和心脏交感神经通路激活的影响。小鼠接受 METH(2mg/kg,ip)治疗 10 天,然后自发戒断 7 天。通过免疫组织化学测量下丘脑室旁核(PVN)和终纹床核的卵圆形区(ovBNST)中促肾上腺皮质释放因子(CRF)、c-Fos 和 CRF/c-Fos 神经元的数量,这两个区域与心脏交感神经控制有关。同时,在心脏中测量儿茶酚-O-甲基转移酶(COMT)、酪氨酸羟化酶(TH)和热休克蛋白 27(Hsp27)的水平。在大脑中,慢性 METH 处理增强了 PVN 和 ovBNST 中 c-Fos 神经元和带有 c-Fos 信号的 CRF 神经元(CRF/c-Fos)的数量。METH 戒断增加了 CRF 神经元的数量。在心脏中,METH 给药诱导可溶性(S)-COMT 和膜结合(MB)-COMT 的增加,而磷酸化(p)-TH、Hsp27 或 pHsp27 没有变化。同样,METH 戒断增加了 S-和 MB-COMT 的表达。与慢性处理相反,METH 戒断增加了心脏中(p)TH 和(p)Hsp27 的水平。总的来说,我们的结果表明,慢性 METH 给药和戒断激活了与心脏交感神经控制相关的大脑 CRF 系统,并指出 METH 戒断诱导了心脏交感神经通路的激活。我们的发现为 METH 使用相关心血管风险的机制提供了进一步的见解,并为其治疗提出了目标。